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CEBPA (CCAAT/Enhancer Binding Protein Alpha) encodes a 42-kDa transcription factor 55 essential for differentiation of myeloid progenitor cells. CEBPA regulates expression of the 56 granulocyte colony-stimulating factor receptor (CSF3R) gene which plays a prominent role in 57 granulocyte differentiation 1 . Homozygous deletion of CEBPA in mouse hematopoietic cells leads 58 to a selective loss of CSF3R expression and results in a complete block of neutrophil 59 differentiation 1,2 . Acquired mutations in CSF3R are present in majority of chronic neutrophilic 60 leukemias (CNL) and atypical (BCR-ABL1-negative) chronic myeloid leukemias (aCML) 3 , which 61 are neoplasms affecting the granulocytic lineage. CSF3R mutations comprise either the 62 membrane-proximal missense mutations or C-terminal truncating mutations proposed to lead to 63 ligand independence and ligand hypersensitivity, respectively 4 . CSF3R mutations have also 64 been described in patients with congenital neutropenia treated with granulocyte colony 65 stimulating factor therapy (G-CSF) upon acute myeloid leukemia (AML) transformation 5, 6 but 66 they have only been reported in < 1-2% of AML. 3, 7, 8 . 67
Two major categories of collaborating CEBPA mutations have been described in human AML: 68 (i) frameshift insertions or deletions affecting the N-terminal region resulting in a loss of the 42 69 kDa protein and overexpression of a shorter 30 kDa CEBPA protein proposed to exhibit a 70 dominant negative activity 9 , and (ii) in frame mutations in the C-terminal region that alter the 71 basic leucine zipper (bZIP) domain 10 . CEBPA-mutated AML carrying mutations in both alleles 72 (CEBPA biallelic or CEBPA bi AML) represent a distinct subgroup characterized by a normal 73 karyotype and favorable prognosis 11, 12 . In most specimens a combination of N-terminal 74 frameshift and C-terminal in frame mutations are observed, hereafter called typical CEBPA bi 75 AML. Other combinations of CEBPA bi mutations, hereafter called atypical CEBPA bi AML, were 76 also described 13, 14 . 77
Gene expression studies have shown that CEBPA bi samples, but not monoallelic mutations, 78 have a distinctive gene expression profile [15] [16] [17] [18] , and analyses of small series indicated a 79 possibility that this profile is shared by some atypical CEBPA bi AML 15 . Mutations in genes such 80 as GATA2, WT1 and TET2 have been described thus far in CEBPA bi specimens [19] [20] [21] [22] , including 6 81 specimens reported in the TCGA cohort 7 . 82
We previously used comparative transcriptomic approaches to report the mutational and 83 transcriptional landscapes of MLL 23 , EVI1 24 , NUP98-NSD1 25 and CBF 26 AML subgroups 84 included in the Leucegene cohort, and also demonstrated that chemical interrogation of a 85 mutation could identify new therapeutic targets in AML 23 . We hereby describe RNA-sequencing 86 analysis of the 14 CEBPA bi AML specimens included in our collection, and report new activating 87
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Normal myeloid populations 121
The following populations were sorted from normal bone marrow on a BD Aria II cell sorter 122 using the corresponding panels: promyelocytes: propidium iodide (PI)-/CD34-/CD16-/CD11b-123 /CD33+/CD15+, myelocytes: PI-/CD34-/CD16-/CD11b+/CD13-/CD15+/CD33+, 124 metamyelocytes:
PI-/CD34-/CD16int/CD11b+/CD33int/CD15+, band and segmented 125 granulocytes: PI-/CD34-/CD16high/CD11b+/CD33int/CD13+/CD15+. Granulocytes were sorted 126 from normal peripheral blood by gating on SSC++CD33int cells. Fresh normal bone marrow was 127 purchased from Lonza. The following FACS antibodies were used: CD33 PE (BD Bioscience 128 555450), CD34 APC (BD Bioscience 555824), CD11b PE-Cy5 (BD
130
Cell culture and chemical screen 131
Preparation of cell culture from frozen AML mono-nucleated cells and chemical screen were 132 performed as previously described 23,27 using serum-free media supplemented with cytokines, 133 500 nM SR1 (Alichem) and 500 nM UM729 (IRIC Positions of mutations are illustrated in Figure 1A and detailed in supplemental Table 3 . 157
Baseline characteristics of cohorts are indicated in Table 1 
The typical CEBPA bi specimens are best characterized by a total of 95 genes ( Figure 1B and 162 supplemental Figure 1C ). This analysis also 173
showed that 4 out of 7 atypical CEBPA bi samples clustered with the CEBPA bi (light blue dots in 174 dashed zone, Figure 1C Figure 1D) ). No recurrent CEBPA mutation pattern was found in the 4 atypical CEBPA bi GEP+ 177 specimens thus suggesting that expression profiling may help to categorize such patients 178 ( Figure 1D Figure 1G ). CSF3R expression is lower in CEBPA bi 185 GEP+ specimens only (right panel in Figure 1G ). 186 The most frequent mutations in CEBPA bi subgroup affected CSF3R in 4/14 (29%) (Figure 2A 199 and supplemental Figure 2 ). CSF3R mutations were not previously reported in CEBPA bi AML 200 and they were strongly associated with this subgroup, as only 3 additional CSF3R mutations 201 were identified in the entire cohort (4/14 vs 3/401, p < 0.0001, Figure 2C ). CSF3R T618I 202 "membrane proximal" mutation characterized all 4 CEBPA bi samples. In contrast, this specific 203 point mutation was not found in the 3 non-CEPBA specimens, which carried non-sense or 204 frameshift CSF3R mutations ( Figure 2C and supplemental Table 7 ). A single T618I mutation 205 was observed in the TCGA in a sample with CEBPA monoallelic mutation 7 . CSF3R mutations 206 were also found in 1.9% of pediatric AML in an analysis that did not perform CEBPA mutational 207 analysis 8 . Rare CSF3R T618I mutations were also identified in AML samples with no CEBPA 208 mutation, indicating they can also occur, at a low frequency in other genetic contexts 31 . VAF 209 analysis suggests that co-occurrence of CSF3R and CEBPA mutations were found in the 210 dominant clone (supplemental Table 8 ). 211
CSF3R
T618I mutated CEBPA bi specimens did not show any distinctive clinical laboratory features 212 (supplemental Table 9 ) but presented a defined transcriptomic profile (supplemental Figure 3 ) 213 when compared to their wild-type CSF3R counterparts. GO term enrichment analyses showed a 214
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CSF3R signals predominantly through JAK-STAT pathway 3 . Considering the high frequency of 220 activating T618I CSF3R mutations detected in CEBPA bi AML we conducted a targeted chemical 221 screen employing a collection of compounds enriched for JAK inhibitors (n=6, supplemental 222 Table 11 ). For this study, we used our recently described culture system that preserves integrity 223 of leukemia blasts and leukemia stem cell activity 27 . Cytotoxic activity of the selected molecules 224 was measured in dose response studies on a total of 28 primary AML specimens including all 225
14 CEBPA bi AML samples described in the previous sections and 14 randomly selected 226
CEBPA
wt normal karyotype controls (supplemental Table 12 ). 227
Responses of CEBPA bi specimens (n=14) and normal karyotype CEBPA wt AML (n=14) to the 228 positive controls cytarabine and daunorubicin were comparable ( Figure 3A -B and supplemental 229 Figure 4A , compounds IC 50 in supplemental Table 13 and p-values in supplemental Table 14) . 230
Likewise these 2 AML subgroups were equally sensitive to the multi-kinase inhibitors sorafenib 231 and dasatinib reported to lack JAK inhibitory activity ( Figure 3A ,C and supplemental Figure 4B ). 232
In contrast, CEBPA bi AML were statistically more sensitive than control NK AML to inhibitors 233 which more specifically targeted JAK proteins (ruxolitinib, CYT387, tofacitinib and AZD1480: 234 Figure 3A ,D and supplemental Figure 4C ). Although of high potency, compounds such as 235 lestaurtinib and TG-101348 which target JAK and other kinases were less discriminatory (red 236 dots in Figure 3A , and supplemental Figure 4D ). 237
Specimens with activating mutations in CSF3R were among the most sensitive to ruxolitinib 238 (orange dots in Figure 3E ) and to the other 3 most specific JAK inhibitors (supplemental For personal use only. on August 16, 2017. by guest www.bloodjournal.org From
The 11 CEBPA bi GEP+ specimens tested, irrespective of their CSF3R mutation status, were 247 equally sensitive to the JAK inhibitors ( Figure 3E , third column for ruxolitinib). The uniform 248 response to JAK inhibition in the homogeneous CEBPA bi GEP+ subgroup stands in sharp 249 contrast to the heterogeneous response determined for the NK control group ( Figure 3E , fourth 250 column) and the GEP-specimens and strengthens our hypothesis that the CEBPA bi GEP-and 251 GEP+ are distinct entities ( Figure 3G and supplemental Figure 7) . 252
These results suggest that networks or pathways upstream of JAK-STAT are aberrantly 253 activated in the majority of CEBPA bi GEP+ specimens and, less frequently in other NK AML. 254
Activating mutations in CSF3R could account for responses in 3 out of 11 CEBPA bi GEP+, but 255 not for either the remaining 8 CEBPA bi GEP+ specimens and or the sensitive NK AML 256 specimens (supplemental Table 15 ). To further investigate this observation, we systematically 257 analyzed all variants present in genes (n=167) relevant to JAK network excluding its proposed 258 downstream targets (supplemental Table 2 ). In the addition of the CSF3R T618I mutation 259 described above we detected 2 recurrent variants, JAK2 L383V and EPHB6 S166F, 260 characterized by a 7.4-and >117-fold observed/expected enrichment ratios, respectively 261 (supplemental Table 16 ). Both variants were confirmed to be germline. Interestingly, the S166F 262 substitution within the ligand-binding domain of EPHB6 is predicted to affect the ligand binding 263 and consequently activity of this receptor. Moreover, this variant allele detected exclusively in 2 264
bi GEP+ samples has never been described before. We also found a large number of 265 non-recurrent variants in several cytokine receptors in these specimens (supplemental Table  266 16), but larger patient cohorts would be required to select potential candidates for functional 267 validation studies. 268
In summary, this study documents for the first time recurrent activating CSF3R mutations in 269 AML with a strict association to the rare CEBPA bi genetic subgroup. Targeted analyses in other 270 cohorts will precise the frequency of CSF3R mutation in CEBPA bi and non-CEBPA bi AML as 271 well. Of interest Maxson JE recently presented similar findings (Maxson JE et al, abstract #174, 272 ASH annual meeting 2015). As might be anticipated, these CSF3R mutated specimens are 273 sensitive to JAK inhibition. Most notably, our study also shows that CEBPA bi GEP+ AMLs are 274 uniformly sensitive to JAK inhibition raising the possibility that selective genetic pressure 275 resulted in a dependence on the JAK-STAT signaling pathway. An unexpected frequency of 276 variant alleles in JAK/STAT network genes provides a pipeline for future exploration. 277
Considering that most molecules tested herein are available drugs, these studies suggest that 278 
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